metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Tumores gástricos estromales: factores pronósticos y tratamiento quirúrgico
Journal Information
Vol. 72. Issue 4.
Pages 200-204 (October 2002)
Share
Share
Download PDF
More article options
Vol. 72. Issue 4.
Pages 200-204 (October 2002)
Full text access
Tumores gástricos estromales: factores pronósticos y tratamiento quirúrgico
Gastric stromal tumors: Prognostic factors and surgical treatment
Visits
4324
J.I. González Muñoz1, M. Angoso Clavijo, L. Giménez Alvira, R. Urioste Arana, A. Colas Vicente
Servicio de Cirugía de Urgencias
C. Salas Antona
a Servicio de Anatomía Patológica. Hospital Universitario Puerta de Hierro. Madrid
This item has received
Article information
Resumen
Introducción

Los criterios para determinar el grado de malignidad de los tumores gástricos estromales no están claramente definidos, por lo que el tratamiento quirúrgico de estas lesiones es controvertido.

Métodos

Se han estudiado las características clínicas, morfológicas y quirúrgicas de 49 pacientes diagnosticados de tumor gástrico estromal entre 1968 y 1999. Se han analizado las tablas de frecuencias y se ha llevado a cabo un estudio de supervivencia.

Resultados

Se han hallado 29 tumores malignos, mientras que el resto eran benignos. Los síntomas más frecuentes consistieron en un síndrome constitucional, hemorragia digestiva alta y masa abdominal en el 20% de los casos. El análisis de la supervivencia demostró que la presencia de masa abdominal, el tamaño tumoral mayor de 10 cm y la necrosis tumoral son indicadores de mal pronóstico, mientras que la presencia de ulceración indica buen pronóstico. Un índice mitótico elevado (> 10) y una resección quirúrgica amplia no tienen impacto en la supervivencia de estos pacientes.

Conclusiones

Recomendamos una resección completa pero limitada de estos tumores dada la menor complejidad técnica, la menor morbilidad y el idéntico pronóstico que los asociados con resecciones más amplias.

Palabras clave:
Tumores estromales gástricos
Pronóstico
Tratamiento
Introduction

The criteria for determining the degree of malignancy of gastric stromal tumors (GST) haveyet to be clearly defined; thus the surgical treatment of these lesions is controversial.

Method

We analyzed the clinical, morphological and surgical features of 49 patients diagnosed with GST between 1968 and 1999. Frequency tables and survival were analyzed.

Results

Twenty-nine tumors were benign and 20 were malignant. In 20% of the patients, symptoms consisted of constitutional syndrome, upper gastrointestinal hemorrhage and abdominal mass.

The survival analysis demonstrated that the presence of abdominal mass, tumor size more than 10 cm and tumor necrosis were indicators of poor prognosis while the presence of ulceration indicated favorable prognosis. Elevated mitotic index (>10) and wide surgical resection margin had no effect on thesurvival of these patients.

Conclusions

We recommend complete but limited surgical resection of gastric stromal tumors since patient survival is similar to that associated with more ample resections.

Key words:
Gastric stromal tumors
Prognosis
Treatment
Full text is only aviable in PDF
Bibliografía
[1.]
M.B. Amin, Mack, M.D. Linden, J.I. Kubus, R.J. Zarbo.
Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Correlation with mitotic count and clinical outcome.
Am J Clin Pathol, 100 (1993), pp. 428-432
[2.]
H.D. Appelman, E.B. Helwig.
Gastric epithelioid leiomyoma and leiomyosarcoma (leiomyoblastoma.
Cancer, 38 (1976), pp. 708-728
[3.]
J.R. Elizalde, F. Borda, F.J. Jiménez, A. Martínez, C. Valenti, J. Herrera.
Tumor estromal gástrico gigante simulando lesión ocupacional hepática.
Rev Esp Enf Dig, 89 (1997), pp. 561-564
[4.]
H.L. Evans.
Smooth muscle tumors of the stomach. Areview with special reference to gross pathology.
Medicine (Baltimore), 30 (1951), pp. 81-181
[5.]
G. Farrugia, C.H. Kim, C. Grant, A.R. Zinsmeister.
Leiomyosarcoma of the stomach: determinants of long-term survival.
Mayo Clin Proc, 67 (1992), pp. 533-536
[6.]
D.W. Franquemont.
Differentiation and risk asessment of gastrointestinal stromal tumors.
Am J Clin Pathol, 103 (1995), pp. 41-47
[7.]
C.E. Fuller, G.T. Williams.
Gastrointestinal manifestations of type I neurofibromatosis (von Recklinghausen’s disease.
Histopathology, 19 (1991), pp. 1-11
[8.]
C.S. Grant, C.H. Kim, G. Farrugia, A. Zinsmeister, J.R. Goellner.
Gastric leiomyosarcoma: prognostic factors and surgical management.
Arch Surg, 126 (1991), pp. 985-990
[9.]
A. Gutiérrez Calvo, J. Nuño Vázquez, J. García Borda, J. Pascual Montero, J.I. López Fernández, I. Fernández Blanco, et al.
Tumores gástricos de estirpe muscular.
Rev Quir Esp, 15 (1988), pp. 231-236
[10.]
L.J. He, B.S. Wang, C.C. Chen.
Smooth muscle tumorurs of the digestive tract: report of 160 cases.
B J Surg, 75 (1988), pp. 184-186
[11.]
R.W. Kieffer, B. McSwain, R.B. Adkins.
Sarcoma of the gastrointestinal tract: review of 40 cases.
Am Surg, 48 (1982), pp. 167-169
[12.]
E.D. Palmer.
Benign intramural tumors of the stomach. A review with special reference to gross pathology.
Medicine (Baltimore), 30 (1951), pp. 81-181
[13.]
P.C. Lindsay, N. Ordóñez, J.H. Raaf.
Gastric leiomyosarcoma: clinical and pathological review of fifty patients.
J Surg Oncol, 18 (1981), pp. 399-421
[14.]
P.C. McGrath, J. Neifeld, W. Lawrence, S. Kay, J.S. Horsley, G.A. Parker.
Gastrointestinal sarcomas: analysis of prognostic factors.
Ann Surg, 206 (1987), pp. 706-710
[15.]
B.K. Morgan, C. Compton, M. Talbert, W.I. Gallagher, W.C. Wood.
Benign smooth muscle tumors of the gastrointestinal tract.
Ann Surg, 211 (1990), pp. 63-66
[16.]
E.H. Ng, R.E. Pollock, M.F. Munsell, E.N. Atkinson, M.M. Romsdahl.
Prognostic factors influencing survival in gastrointestinal leiomyosarcoma.
Ann Surg, 215 (1992), pp. 68-77
[17.]
Y.T.N. Lee, H. Silberman, K.B. Deck.
Leiomyosarcoma of the gastrointestinal tract: should we consider metastases to regional lymph nodes?.
J Surg Oncol, 15 (1980), pp. 319-321
[18.]
F. Raafat, W.D. Salman, K. Roberts, L. Ingram, R. Rees, J.R. Mann.
Carney’s triad: gastric leiomyosarcoma, pulmonary chondroma and extra-adrenal paraganglioma in young females.
Histopathology, 10 (1986), pp. 1325-1333
[19.]
Nieto Prieto, J.P. Pérez Robledo, J.A. Rodríguez Montes, R. Corripio, M.L. García Sancho.
Leiomiosarcoma intestinal perforado.
Rev Esp Enf Dig, 90 (1998), pp. 730-731
[20.]
M. Rauchod, R.L. Kempson.
Smooth muscle tumors of the gastrointestinal tract and retroperitoneum.
Cancer, 39 (1977), pp. 255
[21.]
R. Ray, S.R. Tahan, C. Andrews, H. Goldman.
Stromal tumors of the stomach: prognostic value of the PCNA index.
Modern Pathol, 7 (1994), pp. 26-30
[22.]
J. Rosay.
Ackerman’s surgical pathology: gastrointestinal tract.
8th ed., pp. 645-647
[23.]
M. Roy, S.C. Sommers.
Metastatic potencial of gastric leiomyosarcoma.
Pathol, 185 (1985), pp. 874-877
[24.]
F. Fernández, J.P. Paredes, P. García, J. Potel.
Tumoración estromal gastrointestinal.
Cir Esp, 69 (2001), pp. 408-410
[25.]
A. Schmidt, K. Lockwood.
Benign lesions of the esophagous.
Acta Chir Scand, 133 (1967), pp. 640-644
[26.]
M.H. Shiu, G.H. Farr, D.N. Papachristou, S.I. Hajdu.
Myosarcomas of the stomach: natural history, prognostic factors and management.
Cancer, 49 (1982), pp. 177-187
[27.]
W. Smithwiek, J.L. Biesecker, P.M. Leand.
Leiomyoblastoma: behaviour and prognosis.
Cancer, 24 (1969), pp. 996-1003
[28.]
D. Liev, Y. Kariv, J. Issakov, H. Merhav, E. Berger, O. Merimsky, et al.
Gastrointestinal sarcomas.
[29.]
J.I. Tubia, A. Sánchez, N. Partearroyo, I. Galarriaga, E. López de Heredia, M. Palomar, et al.
Tumor estromal CD34 de localización yeyunal.
Cir Esp, 67 (2000), pp. 100-112
[30.]
T. Ueyama, K.J. Guo, H. Hashimoto, Y. Daimaru, M. Eujoji.
A clinicopathologic and immunohistochemical study of gastro-intestinal tumors.
Cancer, 69 (1992), pp. 947-955
Copyright © 2002. Asociación Española de Cirujanos
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos